Why the study?
Low plasma adiponectin occurs in obesity, type 2 diabetes mellitus, and NAFLD, prompting assessment of its correlation with carotid intima-media thickness as an atherosclerosis marker in Egyptian patients with NAFLD.
Hypoadiponectinemia correlates with increased carotid intima-media thickness in obese patients with NAFLD, suggesting it may serve as an indicator of cardiovascular risk in this population.
Answers are grounded in this paper and cite their sources.
Inverse adiponectin-CIMT association limited to obese NAFLD; leaves open biomarker role and needs prospective confirmation.
Background and Aim. Low plasma adiponectin has been found in both obese subjects and patients with type 2 diabetes mellitus (T2DM). Also, it was reported in patients with nonalcoholic fatty liver disease (NAFLD). We assessed plasma adiponectin and its correlation with carotid intima-media thickness (CIMT), as a marker of atherosclerosis, in Egyptian patients with NAFLD. Methods and Results. The study included 200 Egyptian subjects. They were divided into four equal groups: group 1: obese patients with NAFLD and T2DM (O+/NAFLD+/DM+), group 2: nonobese patients with NAFLD and T2DM (O-/NAFLD+/DM+), group 3: obese nondiabetic patients with NAFLD (O+/NAFLD+/DM-), and group 4: nonobese healthy control subjects. Plasma adiponectin was measured using ELISA (enzyme-linked immunosorbent assay) technique. Ultrasonography was used to diagnose NAFLD. CIMT was assessed using Doppler ultrasonography. Plasma adiponectin was significantly lower and CIMT was significantly higher in O+/NAFLD+/DM+, as compared with O-/NAFLD+/DM+, O+/NAFLD+/DM-, and control subjects ( p < 0.001 for all). A significant negative correlation was found between adiponectin and CIMT in obese patients with NAFLD ( p < 0.05 ), but not in patients with NAFLD and T2DM. The significant independent predictors of CIMT were diabetes duration, BMI (body mass index), albumin/creatinine ratio, and cholesterol. Conclusion. Plasma adiponectin is inversely correlated with CIMT in obese patients with NAFLD, but not in patients with NAFLD and T2DM. Hypoadiponectinemia could be a good indicator of cardiovascular risk in obese patients with NAFLD, with or without T2DM, but not in nonobese patients with NAFLD.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: